Introduction:
In a recent interview with HCPLive, Dr. Shai Efrati, MD, PhD, the co-Founder and Chair of Aviv Scientific’s Medical Advisory Board, discussed a groundbreaking study that unveils the potential of hyperbaric oxygen therapy (HBOT) in providing relief for fibromyalgia induced by traumatic brain injury. As the Founder and Director of the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, Dr. Efrati sheds light on the promising results of his team’s research, offering new hope for those suffering from fibromyalgia.
The Journey from Pilot Study to Fibromyalgia Treatment:
Dr. Efrati’s journey began a decade ago with a pilot study that demonstrated the efficacy of hyperbaric oxygen therapy in eliminating fibromyalgia symptoms. Recognizing fibromyalgia as a central sensitization syndrome linked to brain signal interpretation issues, the team explored regenerating damaged brain tissue. Building on classical indications like stroke and multi-brain injuries, they developed a unique protocol of HBOT triggering stem cell replication, generating new blood vessels, and activating repair mechanisms in the brain.
Evaluating the Efficacy:
Fibromyalgia and Hyperbaric Oxygen Therapy: The recent study focused on evaluating the efficacy of HBOT in patients with fibromyalgia induced by brain injuries. The team randomized patients into two treatment groups – one receiving traditional medications like pregabalin (Lyrica) and duloxetine (Cymbalta), and the other undergoing a dedicated protocol of hyperbaric oxygen therapy. Dr. Efrati and his team meticulously analyzed various parameters, including pain levels, quality of life, and physical performance before and after the HBOT treatment.
Promising Results:
The results revealed a significant relief of fibromyalgia symptoms in patients who underwent hyperbaric oxygen therapy. This breakthrough offers a new perspective on treating fibromyalgia, addressing the root cause induced by brain injuries through a targeted and innovative therapeutic approach.
Seeking More Information:
For individuals seeking more information about Dr. Shai Efrati’s groundbreaking research and the potential of hyperbaric oxygen therapy for fibromyalgia, a dedicated contact number is provided: +1 (916) 912-3214. This allows interested parties to connect with professionals who can provide insights into the study, the therapy, and its potential application for fibromyalgia treatment.
Conclusion:
Dr. Shai Efrati’s research presents a significant stride in the medical community’s understanding of fibromyalgia and its potential treatment through hyperbaric oxygen therapy. As promising results emerge, individuals grappling with fibromyalgia-induced by traumatic brain injury may find new hope in this innovative and effective therapeutic approach.
